公开(公告)号：US20240226251A1

公开(公告)日：2024-07-11

申请号：US17870093

申请日：2022-07-21

Applicant: Allergan, Inc.

Inventor： James Oliver Dolly ,  Tomas Zurawski ,  Ron Broide ,  Amy Brideau-Andersen ,  James Cunningham ,  Gregory Nicholson

IPC: A61K38/48 ,  A61K45/06 ,  A61K47/18 ,  C12N9/64

CPC classification number: A61K38/4893 ,  A61K45/06 ,  A61K47/18 ,  C12N9/6489 ,  C12Y304/24069

Abstract: Formulations, methods, and kits comprising at least one Clostridium toxin derivative and at least one chemical depolarizing agent suitable for inducing local, partial or complete muscle paralysis or muscle denervation in a subject are described.

公开(公告)号：US20230158129A1

公开(公告)日：2023-05-25

申请号：US17854334

申请日：2022-06-30

Applicant: ALLERGAN, INC.

Inventor： Cindy WU ,  James Cunningham ,  Marianne Do ,  Ron Broide

IPC: A61K38/48 ,  A61K31/728 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34

CPC classification number: A61K38/4893 ,  A61K31/728 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  C12Y304/24069

Abstract: Pharmaceutical compositions that extend the effect and duration of a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a non-cross-linked hyaluronic acid or salt thereof as described in the application, a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine. N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.

公开(公告)号：US20220096609A1

公开(公告)日：2022-03-31

申请号：US17429237

申请日：2020-02-05

Applicant: Allergan, Inc.

Inventor： James Oliver Dolly ,  Tomas Zurawski ,  Ron Broide ,  Amy Brideau-Andersen ,  James Cunningham ,  Gregory Nicholson

IPC: A61K38/48 ,  A61K47/18 ,  A61K45/06 ,  C12N9/64

Abstract: Formulations, methods, and kits comprising at least one Clostridium toxin derivative and at least one chemical depolarizing agent suitable for inducing local, partial or complete muscle paralysis or muscle denervation in a subject are described.